A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Patients With Active Ankylosing Spondylitis
Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 20 Oct 2015
At a glance
- Drugs Ixekizumab (Primary) ; Adalimumab
- Indications Ankylosing spondylitis
- Focus Registrational; Therapeutic Use
- Acronyms SPIRIT-A1
- Sponsors Eli Lilly
- 21 Jan 2014 Status changed from recruiting to withdrawn prior to recruitment according to ClinicalTrials.gov record.
- 05 Oct 2013 Ne source identified and integrated (European Clinical Trials Database: EudraCT2011-002325-22).
- 26 Sep 2013 Status changed from not yet recruiting to recruiting as reported by European Clinical Trials Database.